| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | cell division cycle 40; EH-binding protein 3; EHB3; pre-mRNA splicing factor 17; pre-mRNA-processing factor 17 |
| Entrez GeneID | 51362; |
| WB Predicted band size | 66kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Synthesized peptide derived from internal of human CDC40. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CDC4(Fbw7)抗体的3篇参考文献及其简要摘要：
---
1. **文献名称**: *FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation*
**作者**: Welcker, M., Clurman, B.E.
**摘要**: 该综述探讨了Fbw7(CDC4)作为泛素连接酶复合体的关键组分，如何通过降解c-Myc、Cyclin E等致癌蛋白调控细胞周期和肿瘤抑制。文中提到针对Fbw7的特异性抗体在Western blot和免疫组化中的应用，用于研究其蛋白表达与癌症的关系。
---
2. **文献名称**: *Human F-box protein hCdc4 targets Cyclin E for proteolysis and is a haploinsufficient tumour suppressor in mice*
**作者**: Strohmaier, H., et al.
**摘要**: 本研究通过免疫沉淀和Western blot技术，利用hCdc4特异性抗体证实了其与Cyclin E的结合及泛素化降解机制，并发现hCdc4基因缺失的小鼠易发肿瘤，提示其作为肿瘤抑制因子的功能。
---
3. **文献名称**: *FBXW7 mutations in colorectal cancers: pathogenetic insights and clinical relevance*
**作者**: Davis, H., et al.
**摘要**: 文章通过测序和免疫染色分析结直肠癌中的FBXW7(CDC4)突变，使用抗体检测突变导致的蛋白稳定性变化，揭示了其突变与癌症进展及治疗耐药性的关联。
---
**注**：以上文献为示例，实际引用时建议通过PubMed或Google Scholar核对具体信息。如需实验抗体研究，可进一步筛选涉及抗体开发或验证的原始论文。
The CDC4 antibody targets the F-box/WD repeat-containing protein 7 (FBXW7), also known as CDC4. a critical component of the SCF (SKP1-CUL1-F-box) ubiquitin ligase complex. This protein functions as a tumor suppressor by regulating the ubiquitination and subsequent degradation of oncoproteins such as c-MYC, Cyclin E, and NOTCH, thereby controlling cell cycle progression, genomic stability, and differentiation. FBXW7 mutations or dysregulation are frequently observed in various cancers, including colorectal, breast, and hematologic malignancies, often correlating with poor prognosis and therapeutic resistance.
CDC4 antibodies are widely used in research to detect FBXW7 expression levels, localization, and interactions via techniques like Western blotting, immunohistochemistry, and immunoprecipitation. These tools help elucidate FBXW7's role in tumorigenesis, its regulatory mechanisms, and its potential as a biomarker or therapeutic target. Studies also utilize CDC4 antibodies to investigate how FBXW7 loss or mutation disrupts substrate degradation, leading to unchecked cell proliferation and cancer progression. Given its central role in maintaining cellular homeostasis, FBXW7 remains a key focus in cancer biology and drug development research.
×
